1. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB (Alliance)‏
by John C. Byrd, Amy S. Ruppert, Nyla A. Heerema, Alese E. Halvorson, Eva Hoke, Mitchell R. Smith, John E. Godwin, Stephen Couban, Todd A. Fehniger, Michael J. Thirman, Martin S. Tallman, Frederick R. Appelbaum, Richard M. Stone, Sue Robinson, Julie E. Chang, Sumithra J. Mandrekar, and Richard A. Larson
BloodAdv
Volume 2(14):
July 24, 2018
© 2018 by The American Society of Hematology

2. John C. Byrd et al. Blood Adv 2018;2:1705-1718
© 2018 by The American Society of Hematology

3. CONSORT diagram.
CONSORT diagram. Arm A = FR. Arm B = FR+L. Arm C = FCR. Arm D = FCR+L.
John C. Byrd et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

4. PFS and OS. (A) PFS for patients with non-del(11q) disease and assigned to FR, FR+L, or FCR. (B) PFS for patients with del(11q) disease and assigned to FCR or reassigned to FCR+L.
PFS and OS. (A) PFS for patients with non-del(11q) disease and assigned to FR, FR+L, or FCR. (B) PFS for patients with del(11q) disease and assigned to FCR or reassigned to FCR+L. (C) OS for patients with non-del(11q) disease and assigned FR, FR+L, or FCR. (D) OS for patients with del(11q) disease and assigned to FCR or reassigned to FCR+L.
John C. Byrd et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology